

Dietmar Trenk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7422819/publications.pdf>

Version: 2024-02-01

40
papers

7,384
citations

201385

27
h-index

288905

40
g-index

40
all docs

40
docs citations

40
times ranked

5404
citing authors

#	ARTICLE	IF	CITATIONS
1	Determinants of fibrotic atrial cardiomyopathy in atrial fibrillation. A multicenter observational study of the RETAC (reseau européen de traitement des troubles du rythme cardiaques)-group. <i>Clinical Research in Cardiology</i> , 2022, 111, 1018-1027.	1.5	7
2	Echocardiographic and Electrocardiographic Determinants of Atrial Cardiomyopathy Identify Patients with Atrial Fibrillation at Risk for Left Atrial Thrombogenesis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1332.	1.0	5
3	Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study. <i>Clinical and Translational Science</i> , 2022, 15, 1204-1214.	1.5	4
4	Impact of On-Clopidogrel Platelet Reactivity on Incidence of Peri-Interventional Bleeding in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Journal of Clinical Medicine</i> , 2022, 11, 2871.	1.0	1
5	Echocardiographic diagnosis of atrial cardiomyopathy allows outcome prediction following pulmonary vein isolation. <i>Clinical Research in Cardiology</i> , 2021, 110, 1770-1780.	1.5	8
6	Left Atrial Hypertension, Electrical Conduction Slowing, and Mechanical Dysfunction – The Pathophysiological Triad in Atrial Fibrillation-Associated Atrial Cardiomyopathy. <i>Frontiers in Physiology</i> , 2021, 12, 670527.	1.3	6
7	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 203-210.	1.4	69
8	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 3132-3140.	1.0	52
9	Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2020, 173, 436-444.	2.0	44
10	Ticagrelor or Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 2329-2337.	1.6	26
11	Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2436-2446.	1.2	41
12	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1067-1077.	2.3	32
13	Ultrastructural, transcriptional, and functional differences between human reticulated and non-reticulated platelets. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2034-2046.	1.9	34
14	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	1.1	366
15	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2019, 381, 1524-1534.	13.9	543
16	Evaluation of an Alternative Staining Method Using SYTO 13 to Determine Reticulated Platelets. <i>Thrombosis and Haemostasis</i> , 2019, 119, 779-785.	1.8	18
17	Impact of On-Clopidogrel Platelet Reactivity on Incidence of Hypoattenuated Leaflet Thickening After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 12-18.	1.1	32
18	The Duration of the Amplified Sinus-P-Wave Identifies Presence of Left Atrial Low Voltage Substrate and Predicts Outcome After Pulmonary Vein Isolation in Patients With Persistent Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 531-543.	1.3	67

#	ARTICLE	IF	CITATIONS
19	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€”Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). <i>American Heart Journal</i> , 2018, 198, 152-159.	1.2	24
20	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptorâ€”Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
21	Impact of reticulated platelets on antiplatelet response to thienopyridines is independent of platelet turnover. <i>Thrombosis and Haemostasis</i> , 2016, 116, 941-948.	1.8	21
22	Comparison of Immature Platelet Count to Established Predictors of Platelet Reactivity During Thienopyridine Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 286-293.	1.2	57
23	Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 219-227.	1.1	23
24	How to improve the concept of individualised antiplatelet therapy with P2Y ₁₂ receptor inhibitors â€” is an algorithm the answer?. <i>Thrombosis and Haemostasis</i> , 2015, 113, 37-52.	1.8	43
25	How to improve the concept of individualised antiplatelet therapy with P2Y ₁₂ receptor inhibitors â€” is an algorithm the answer?. <i>Thrombosis and Haemostasis</i> , 2015, 113, 37-52.	1.8	31
26	Genetics of platelet inhibitor treatment. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 642-653.	1.1	37
27	Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: Platelet reactivity in an observational study. <i>Platelets</i> , 2013, 24, 549-553.	1.1	16
28	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2013, 167, 2140-2148.	0.8	113
29	High on-treatment platelet reactivity and P2Y ₁₂ antagonists in clinical trials. <i>Thrombosis and Haemostasis</i> , 2013, 109, 834-845.	1.8	28
30	A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2159-2164.	1.2	569
31	Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 429-436.	5.1	91
32	Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1821.	3.8	980
33	Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2427-2434.	1.2	285
34	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. <i>Journal of the American College of Cardiology</i> , 2010, 56, 919-933.	1.2	1,058
35	Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. <i>Thrombosis and Haemostasis</i> , 2008, 99, 174-181.	1.8	52
36	Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1925-1934.	1.2	523

#	ARTICLE	IF	CITATIONS
37	Identification of 5-HT ₃ receptors on human platelets: Increased surface immunoreactivity after activation with adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP). <i>Thrombosis and Haemostasis</i> , 2008, 99, 784-786.	1.8	33
38	Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention. <i>Circulation</i> , 2007, 116, 2923-2932.	1.6	831
39	Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1742-1750.	1.2	558
40	Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention. <i>Circulation</i> , 2005, 111, 2560-2564.	1.6	363